Citations

Mayo Clinic

Showing 10 of 108599 citations.

Improved Statistical Methods for Evaluation of Stability of In Vitro Diagnostic Reagents
Holland, Mark D. , Kraght, Paul, Akbas, Neval, Budd, Jeffrey R. , Klee, George G.

Statistics in Biopharmaceutical Research | March 31, 2017 | Volume: 9 | Issue: 3 | Pages: 272-278

10.1080/19466315.2017.1305287 Get It

Osteosclerosis Secondary to Metastatic Oligodendroglioma
Maloney, Patrick R. , Yamaki, Vítor Nagai , Kumar, Ravi , Jentoft, Mark E. , Johnson, Derek, Hunt, Christopher , Clarke, Michelle, Johnson, Derek R. , Hunt, Christopher H. , Clarke, Michelle J.

Rare Tumors | March 31, 2017 | Volume: 9 | Issue: 1 | Pages: 42-46

10.4081/rt.2017.6837 | PMID 28435646 Get It

This paper reviews a case of metastatic 1p/19q codeleted oligodendrioglioma causing diffuse osteosclerosis and pain. Primary central nervous system (CNS) tumors rarely metastasize outside the CNS, and metastatic oligodendroglioma is rarer still. The patient in this study had relief of pain after being treated with temozolomide. We discuss this rare presentation and potential treatment options, and review the literature in regards to metastatic oligodendrogliomas.
Hairy Cell Lymphoma: A Potentially Under-Recognized Entity
Hammond, William A. , Swaika, Abhisek, Menke, David M. , Menke, David, Tun, Han W.

Rare Tumors | March 31, 2017 | Volume: 9 | Issue: 1 | Pages: 1-3

10.4081/rt.2017.6518 | PMID 28458788 Get It

Hairy cell leukemia (HCL) is a low grade B-cell lymphoproliferative disorder that typically presents with splenomegaly, cytopenias, and diffuse bone marrow infiltration. There have been few cases in the literature of HCL presenting as lymphomas in extra-nodal locations, such as soft tissues and bones without circulating leukemic cells, splenomegaly, or iliac crest bone marrow involvement. We present an additional case presenting as a thoracic mass, and discuss potential diagnostic pitfalls and management of these rare cases.
Health-related quality of life outcomes following adult cochlear implantation: A prospective cohort study
Sladen, Douglas P. , Peterson, Ann M. , Schmitt, Matt, Olund, Amy P., Teece, Katherine , Dowling, Brittany P., DeJong, Melissa D., Breneman, Alyce, Beatty, Charles W., Carlson, Matthew L. , Neff, Brian A., Hughes-Borst, Becky, Driscoll, Colin L. W., Peterson, Ann, Olund, Amy, Dowling, Brittany , DeJong, Melissa, Driscoll, Colin L., Schmitt, Matthew

Cochlear Implants International | March 31, 2017 | Volume: 18 | Issue: 3 | Pages: 130-135

10.1080/14670100.2017.1293203 | PMID 28248612 Get It

Prediction of Right Ventricular Failure After Ventricular Assist Device Implant: Systematic Review and Meta-Analysis of Observational Studies
Bellavia, Diego , Scardulla, Cesare, Moja, Lorenzo , Pilato, Michele , Kushwaha, Sudhir S. , Senni, Michele , Clemenza, Francesco , Agnese, Valentina , Falletta, Calogero , Romano, Giuseppe , Maalouf, Joseph F., Dandel, Michael , Iacovoni, Attilio , Senni, Michele

European Journal of Heart Failure | March 31, 2017 | Volume: 19 | Issue: 7 | Pages: 926-946

10.1002/ejhf.733 | PMID 28371221 Get It

Abstract Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is associated with increased morbidity and mortality, but the identification of LVAD candidates at risk for RVF remains challenging. We undertook a systematic review and meta-analysis of observational studies of risk factors associated with RVF after LVAD implant. Thirty-six studies published between 1 January 1995 and 30 April 2015, comprising 995 RVF patients out of a pooled final population of 4428 patients, were identified. Meta-analysed prevalence of post-LVAD RVF was 35%. A need for mechanical ventilation [odds ratio (OR) 2.99], or continuous renal replacement therapy (CRRT; OR 4.61, area under the curve 0.78, specificity 0.91) were the clinical variables with the highest effect size (ES) in predicting RVF. International normalized ratio [INR; standardized mean difference (SMD) 0.49] and N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD 0.52) were the biochemical markers that best discriminated between RVF and No-RVF populations, though NT-proBNP was highly heterogeneous. Right ventricular stroke work index (RVSWI) and central venous pressure (CVP) (SMD −0.58 and 0.47, respectively) were the haemodynamic measures with the highest ES in identifying patients at risk of post-LVAD RVF; CVP was particularly useful in risk stratifying patients undergoing continuous-flow LVAD implant (SMD 0.59, P < 0.001, I2 = 20.9%). Finally, pre-implant moderate to severe right ventricular (RV) dysfunction, as assessed qualitatively (OR 2.82), or a greater RV/LV diameter ratio (SMD 0.51) were the standard echocardiographic measurements with the highest ES in comparing RVF with No-RVF patients. Longitudinal systolic strain of the RV free wall had the highest ES (SMD 0.73) but also the greatest heterogeneity (I2 = 74%) and was thus only marginally significant (P = 0.05). Patients on ventilatory support or CRRT are at high risk for post-LVAD RVF, similarly to patients with slightly increased INR, high NT-proBNP or leukocytosis. High CVP, low RVSWI, an enlarged right ventricle with concomitant low RV strain also identify patients at higher risk.
Whole exome sequencing of a patient with suspected mitochondrial myopathy reveals novel compound heterozygous variants in RYR 1
Blackburn, Patrick R. , Selcen, Duygu , Gass, Jennifer , Jackson, Jessica L. , Macklin, Sarah , Cousin, Margot A. , Boczek, Nicole J. , Klee, Eric W. , Dimberg, Elliot L., Kennelly, Kathleen D., Gass, Jennifer M , Atwal, Paldeep S , Cousin, Margot A

Molecular Genetics & Genomic Medicine | March 31, 2017 | Volume: 5 | Issue: 3 | Pages: 295-302

10.1002/mgg3.280 | PMID 28547000 Get It

Abstract Background Pathogenic variants in ryanodine receptor 1 ( RYR 1, MIM # 180901) are the cause of congenital myopathy with fiber‐type disproportion, malignant hyperthermia susceptibility type 1, central core disease of muscle, multiminicore disease and other congenital myopathies. Methods We present a patient with global developmental delay, hypotonia, myopathy, joint hypermobility, and multiple other systemic complaints that were noted early in life. Later she was found to have multiple bone deformities involving her spine, with severe scoliosis that was corrected surgically. She was also diagnosed with ophthalmoplegia, chronic hypercapnic respiratory failure, and hypertension. At 22 years of age she presented to the genetics clinic with a diagnosis of mitochondrial myopathy and underwent whole exome sequencing ( WES ). Results Whole exome sequencing revealed two novel compound heterozygous variants in RYR 1 (c.7060_7062del, p.Val2354del and c.4485_4500del, p.Tyr1495X). Conclusion Review of her clinical, pathologic, and genetic findings pointed to a diagnosis of a congenital myopathy with fiber‐type disproportion.
FLT3 Mutation Testing in Acute Myeloid Leukemia
Viswanatha, David S., Patnaik, Mrinal M. , Gupta, Arjun

JAMA Oncology | March 31, 2017 | Volume: 3 | Issue: 7 | Pages: 991

10.1001/jamaoncol.2017.0257 | PMID 28358966 Get It

Update in General Internal Medicine: Evidence Published in 2016
Szostek, Jason H. , Wieland, Mark L. , Sundsted, Karna K. , Mauck, Karen F. , Wieland, Mark L

Annals of Internal Medicine | March 31, 2017 | Volume: 166 | Issue: 7 | Pages: W11-W15

10.7326/m17-0114 | PMID 28358933 Get It

How I treat autoimmune hemolytic anemia
Go, Ronald S. , Winters, Jeffrey L. , Kay, Neil E. , Go, Ronald S , Winters, Jeffrey L , Kay, Neil E

Blood | March 31, 2017 | Volume: 129 | Issue: 22 | Pages: 2971-2979

10.1182/blood-2016-11-693689 | PMID 28360039 Get It

AbstractAutoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic, prognostic, and therapeutic dilemmas despite being a well-recognized entity for over 150 years. This is because of significant differences in the rates of hemolysis and associated diseases and because there is considerable clinical heterogeneity. In addition, there is a lack of clinical trials required to refine and update standardized and evidence-based therapeutic approaches. To aid the clinician in AIHA management, we present four vignettes that represent and highlight distinct clinical presentations with separate diagnostic and therapeutic pathways that we use in our clinical practice setting. We also review the parameters present in diagnostic testing that allow for prognostic insight and present algorithms for both diagnosis and treatment of the AIHA patient in diverse situations. This is done in the hope that this review may offer guidance in regard to personalized therapy recommendations. A section is included for the diagnosis of suspected AIHA with negative test results, a relatively infrequent but challenging situation, in order to assist in the overall evaluation spectrum for these patients.
PET/MRI: Where might it replace PET/CT?
Ehman, Eric C. , Johnson, Geoffrey B. , Leynes, Andrew P. , Johnson, Geoffrey B. , Villanueva-Meyer, Javier E. , Cha, Soonmee , Larson, Peder E. Z. , Hope, Thomas A. , Johnson, Geoffrey B , Johnson, Geoffrey B

Journal of Magnetic Resonance Imaging | March 31, 2017 | Volume: 46 | Issue: 5 | Pages: 1247-1262

10.1002/jmri.25711 | PMID 28370695 Get It

Simultaneous positron emission tomography and MRI (PET/MRI) is a technology that combines the anatomic and quantitative strengths of MR imaging with physiologic information obtained from PET. PET and computed tomography (PET/CT) performed in a single scanning session is an established technology already in widespread and accepted use worldwide. Given the higher cost and complexity of operating and interpreting the studies obtained on a PET/MRI system, there has been question as to which patients would benefit most from imaging with PET/MRI versus PET/CT. In this article, we compare PET/MRI with PET/CT, detail the applications for which PET/MRI has shown promise and discuss impediments to future adoption. It is our hope that future work will prove the benefit of PET/MRI to specific groups of patients, initially those in which PET/CT and MRI are already performed, leveraging simultaneity and allowing for greater degrees of multiparametric evaluation.Level of Evidence: 5Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2017;46:1247–1262.